

BIOGRAPHICAL SKETCH

Name: Jerome J. Schentag	Position Titles: Professor of Pharmaceutical Sciences and Pharmacy, University at Buffalo School of Pharmacy Chief Executive Officer, CPL Associates LLC		
Institution	Degree	Year	Field of Study
University of Nebraska at Omaha	B.S.	1973	Pharmacy
Philadelphia College of Pharmacy & Science	Pharm.D.	1975	Clinical Pharmacy

Research and Professional Experience:

1973-1975: Staff Pharmacist, Thomas Jefferson University Hospital, Philadelphia PA

1975-1976: Postdoctoral Fellow in Clinical Pharmacokinetics, Department of Pharmaceutics, State University of New York (SUNY) at Buffalo, School of Pharmacy (with Dr. W.J. Jusko)

1976-1978: Clinical Assistant Professor of Pharmaceutics, SUNY at Buffalo School of Pharmacy

1976-1981: Assistant Director, Clinical Pharmacokinetics Laboratory, Millard Fillmore Hospital, Buffalo NY

1977-2000: Consultant Staff, Millard Fillmore Hospital

1977-1980: Member Pharmacy and Therapeutics Committee, Millard Fillmore Hospital

1978-1979: Acting Director, The Clinical Pharmacokinetics Laboratory, Millard Fillmore Hospital

1979-1998: Pharm.D. Admissions Committee, SUNY School of Pharmacy
Member (1979-1984), Chairman (1984-present)

1979-1981: Assistant Professor of Pharmacy and Pharmaceutics, SUNY School of Pharmacy

1981-1986: Associate Professor of Pharmaceutics and Pharmacy, SUNY School of Pharmacy

1981-2000: Director, The Clinical Pharmacokinetics Laboratory, Millard Fillmore Hospital

1982-1998: Member, Antibiotic Review Committee, Millard Fillmore Hospital

1986-present: Professor of Pharmaceutics and Pharmacy, SUNY School of Pharmacy

1988-1989: Chairman, Recruitment Committee for Department of Pharmacy Chair

1988-1989: Member, Recruitment Committee, Department of Pharmacology Chair
SUNY School of Medicine

1989-1993: Director, Center for Clinical Pharmacy Research, SUNY at Buffalo School of Pharmacy

1989-1998: Director, Doctor of Pharmacy Program, SUNY at Buffalo School of Pharmacy

1989-1993: Member, Executive Committee, SUNY at Buffalo School of Pharmacy

1996-1997: Member, Pharmacy Dean Search Committee, SUNY at Buffalo

1996-1999: Member UB Incubator Evaluation Committee SUNY at Buffalo

2000-present: CEO, CPL Associates LLC

Professional Societies: ACCP, ASPET, APhA, ASHP, AACP, ASM, New York Academy of Sciences

Editorial Boards: Pharmacotherapy, Annals of Pharmacotherapy, Antimicrobial Agents and Chemotherapy, Pharmaceutical Research, Clinical Pharmacology and Therapeutics, Pharmaguide to Hospital Medicine

Other Professional Distinctions:

1985-1988: Member, Scientific Advisory Board, Healthcare Instruments and Devices Institute (HIDI), SUNY at Buffalo

1985: Fellow, American College of Clinical Pharmacy

1980-1990: Certificate of Qualification - Toxicology Laboratory Director, New York State Dept. of Health

1988-present: Fellow, Center for Entrepreneurial Leadership, SUNY at Buffalo School of Management

1989: Distinguished Young Alumnus, Philadelphia College of Pharmacy and Science

1989: ASHP Award for Sustained Contributions to the Literature of Hospital Pharmacy

1991: ACCP Russell R. Miller Award

1991: AAPS Research Achievement Award in Clinical Sciences

1994: U.S. Patent #5,279,607 Site Specific Drug Delivery in the GI Tract

1995: U.S. Patent #5,395,366 Noninvasive Fluid Sampling in The GI Tract

1995: APhA Stimulation of Research Award

Publications (representative from a list exceeding 300):

1. Schentag JJ, Jusko WJ, Vance JW, Cumbo TJ, Abrutyn E, DeLattre M, Gerbracht LM. Gentamicin disposition and tissue accumulation on multiple dosing. *J Pharmacokin Biopharm* 5:559-577, 1977.
2. Schentag JJ, Cumbo TJ, Jusko WJ, Plaut ME. Gentamicin tissue accumulation and nephrotoxic reactions. *J Am Med Assoc* 240:2067-2069, 1978.
3. Schentag JJ, Cerra FB, Calleri G, DeGlopper E, Rose JQ, Bernhard H. Pharmacokinetic and clinical studies in patients with cimetidine-associated mental confusion. *Lancet* 1:177-181, 1979.
4. Reitberg DP, Bernhard H, Schentag JJ. Alteration of theophylline clearance and half-life by cimetidine in normal volunteers. *Ann Intern Med* 95:582-585, 1981.
5. Schentag JJ, Cerra FB, Calleri G, Leising M, French MA, Bernhard H. Age, disease, and cimetidine disposition in healthy subjects and chronically ill patients. *Clin Pharmacol Ther* 29:737-743, 1981.
6. Schentag JJ and Gengo FM. Principles of antibiotic tissue penetration and guidelines for pharmacokinetic analysis. *Med Clin North Am* 66:39-49, 1982.
7. Schentag JJ. Specificity of renal tubular damage criteria for aminoglycoside nephrotoxicity in critically ill patients. *J Clin Pharmacol* 23:473-483, 1983.
8. Smith IL, Ziemniak JA, Bernhard H, Eshelman FN, Martin LE, Schentag JJ. Ranitidine disposition and systemic availability in hepatic cirrhosis. *Clin Pharmacol Ther* 35:487-494, 1984.
9. Schentag JJ, Swanson DJ, Smith IL. Dual Individualization - antibiotic dosage calculation from the integration of in vitro pharmacodynamics and in vivo pharmacokinetics. *J Antimicrob Chemother* 15(Suppl A):47-57, 1985.
10. Giacoia GP, Schentag JJ. Pharmacokinetics and nephrotoxicity of continuous intravenous infusion of gentamicin in low birthweight infants. *J Pediatrics* 109:715-719, 1986.
11. McCormack JP, Schentag JJ. The potential impact of quantitative susceptibility tests on the design of aminoglycoside regimens. *Drug Intell Clin Pharm* 21:187-191, 1987.
12. Fink MP, Snyderman DR, Niederman MS, Leeper KV, Johnson RH, Heard SO, Wunderink RG, Caldwell JW, Schentag JJ, Siami GA, Zamek RL, Haverstock DC, Reinhart HH, Echols RM. Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem/cilastatin. *Antimicrob Agents Chemother* 38:547-557, 1994.
13. Rescott DL, Nix DE, Holden P, Schentag JJ. Comparison of two methods for determining in-vitro postantibiotic effect of three antibiotics on *Escherichia coli*. *Antimicrob Agents Chemother*, 32:450-453, 1988.
14. Welage LS, Hejmanowski LG, Wilton JH, Walawander C, Rigan D, Williams JS, Schentag JJ. Comparison of N-methyl-thiotetrazole disposition in healthy volunteers following single IV doses of moxalactam, cefoperazone, and cefotetan. *Antimicrob Agents Chemother* 33:857-861, 1989.
15. Haas CE, Nix DE, Schentag JJ. In vitro selection of resistant *Campylobacter pylori*. *Antimicrob Agents Chemother* 34(9):1637-1641, 1990.
16. Schentag JJ. Criteria for use of antiendotoxin therapy. *J Am Med Assoc* 267:2326-2327, 1992.
17. Schentag JJ, Ballow CH, Fritz AL, Paladino JA, Williams JD, Cumbo TJ, Ali RV, Galletta VA, Gutfeld MB, Adelman MH. Changes in antimicrobial agent usage resulting from interactions among clinical pharmacy, infectious diseases division, and the microbiology laboratory. *Diagn Microbiol Infect Dis* 16:255-264, 1993.
18. Alioth C, Blum RA, D'Andrea DT, Kochak GM, Teng L, Ziehmer BA, Schentag JJ, Chan KKH. Application of dual radiotelemetric technique in studying drug-drug interaction between diclofenac sodium and ranitidine HCL in volunteers. *Pharm Res* 10:1688-1692, 1993.
19. Daniels S, Schentag JJ. Drug interaction studies and safety of famciclovir in healthy volunteers: a review. *Antiviral Chemistry and Chemotherapy* 4 (Suppl 1):57-64, 1993.
20. Peck CC, Barr WH, Benet LZ, Collins J, Desjardins RE, Furst DE, Harter JG, Levy G, Ludden T, Rodman JH, Sanathanan L, Schentag JJ, Shah VP, Sheiner LB, Skelly JP, Stanski DR, Temple RJ, Viswanathan CT, Weissinger J, Yacobi A. Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development. *J Clin Pharmacol* 34:111-119, 1994.
21. Goss TF, Forrest A, Nix DE, Ballow CH, Birmingham MC, Cumbo TJ, Schentag JJ. Mathematical examination of dual individualization principles (II): the rate of bacterial eradication at the same area under the inhibitory curve (AUC) is more rapid for ciprofloxacin than for cefmenoxime. *Annals of Pharmacotherapy* 28:863-868, 1994.
22. Schentag JJ. Understanding and managing microbial resistance in institutional settings. *Am J Health-Syst Pharm* 52(Suppl 2):S9-14, 1995.
23. Hyatt JM, McKinnon PS, Zimmer GS, Schentag JJ. The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. *Clin Pharmacokinet* 28(2):143-160, 1995.
24. Nix DE, Thomas JK, Symonds WT, Spivey JM, Wilton JH, Gagliardi NC, Schentag JJ. Assessment of the nephrotoxic potential of gentamicin alone and combinations of gentamicin with various beta lactam antibiotics. *Ann Pharmacother* 31:696-703, 1997.

25. Hyatt JM, Luzier AB, Forrest A, Ballow CH, Schentag JJ. Modeling the response of pneumonia to antimicrobial therapy. *Antimicrob Agents Chemother.* 41:1269-1274, 1997.
26. Thomas JK, Forrest A, Bhavnani SM, Hyatt JM, Cheng A, Ballow CH, Schentag JJ. Pharmacodynamic evaluation of Factors Contributing to the Selection of Bacterial Resistance in Acutely Ill Patients. *Antimicrob Agents Chemother.* In Press, 1998.
27. Birmingham MC, Rayner CR, Meagher AK, Flavin SM, Batts DH, Schentag JJ. Linezolid in the Treatment of Multi Drug Resistant Gram Positive Infections: Results of the Compassionate Use Experience. *Clin Infect Diseases* In Press, 2002
28. Schentag JJ, Gilliland KK, Paladino JA. What have we learned from Pharmacokinetic and Pharmacodynamic Theories? *Clin Infect Dis* 32 (Suppl 1): s39-s46, 2001